Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Asset Acquisition [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement |
Note 2 – Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement
As described in Note 1, “Organization and Summary of Significant Accounting Policies,” on July 28, 2026, we acquired Vidya pursuant to the Merger Agreement. Under the terms of the Merger Agreement, we issued to the stockholders of Vidya an aggregate of shares of Series A Non-Voting Convertible Preferred Stock, par value $ per share (the “Series A Preferred Stock”). Each share of Series A Preferred Stock is convertible into shares of our common stock, par value $ per share, subject to receiving approval by our stockholders of the issuance of shares of our common stock upon conversion of Series A Preferred Stock and exercise of certain options held by the former equity holders of Vidya that we assumed in the Vidya Acquisition. All the outstanding options to purchase Vidya common stock were assumed by us and were converted into options to purchase an aggregate of shares of our common stock (the “Assumed Options”). The total consideration in connection with the Vidya Acquisition was $175.4 million. We also incurred fees totaling $2.7 million in acquisition costs, of which $0.7 million was paid via shares of Series A Preferred Stock to an advisor.
Pursuant to the Merger Agreement, we agreed to hold a stockholders’ meeting to submit certain matters to our stockholders for consideration, including (i) the issuance of shares of our common stock upon conversion of the Series A Preferred Stock issued in connection with the Vidya Acquisition and exercise of certain Assumed Options pursuant to Nasdaq Listing Rules 5635(a) and 5635(b) (the “Preferred Stock Conversion Proposal”), (ii) the issuance of shares of our common stock upon conversion of the Series A Preferred Stock issued in connection with the 2026 Private Placement pursuant to Nasdaq Listing Rule 5635(d) (the “Minimum Price Proposal”), (iii) approval of the our 2027 Equity Incentive Plan (the “2027 Plan Proposal”), and (iv) approval of the 2027 Employee Stock Purchase Plan (the (“2027 ESPP Proposal” and, collectively with the Preferred Stock Conversion Proposal, the Minimum Price Proposal and the 2027 Plan Proposal, the “Stockholder Matters”).
Subject to the receipt of stockholder approval of the Stockholder Matters, each share of Series A Preferred Stock will automatically convert into shares of our common stock, subject to certain beneficial ownership limitations established by each holder. As a result of the acquisition and related private placement transaction, our equity holders immediately prior to the Vidya Acquisition owned approximately 1.4% of our common stock, equity holders of Vidya immediately prior to the Vidya Acquisition owned approximately 46.0% of our common stock and investors in the 2026 Private Placement owned approximately 52.6% of our common stock, in each case, calculated on a fully diluted basis (assuming the conversion in full of the Series A Preferred Stock) and based on our and Vidya’s implied equity values.
The transaction was accounted for as an asset acquisition in accordance with ASC 805, Business Combinations. Upon completion of the Vidya Acquisition, we obtained control of Vidya’s assets, consisting primarily of in-process research and development (“IPR&D”). We acquired one asset, the underlying intellectual property associated with Vidya’s lead asset, VT-7208, an orally available, covalently binding, irreversible, CNS-penetrant BTKi that comprised more than 90% of Vidya’s assets. Under this method of accounting, the Company was the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Vidya Acquisition: (i) our stockholders hold the majority of the voting rights in the combined company based on their ownership, (ii) Vidya held only one out of the six board of director seats of the combined company, and (iii) the Company’s existing executive management team continued in its respective leadership roles following closing and no former Vidya executive was appointed to a key executive management position of the combined company. In accordance with ASC 805, under the asset acquisition method of accounting, the assets acquired and liabilities assumed are recognized and measured at fair value and no goodwill is recorded or recognized.
Transaction costs of $2.7 million were capitalized as part of the cost of the assets acquired and, together with the acquired IPR&D, were expensed at the acquisition date because the IPR&D has no alternative future use. No goodwill was recognized. We have included the operating results of Vidya since July 28, 2026 in our consolidated financial statements.
The following summarizes the purchase price paid in the Vidya Acquisition (in thousands, except share and per share amounts):
The preliminary fair value of the net assets, liabilities, and IPR&D acquired was as follows (in thousands):
Concurrently with the Vidya Acquisition, on July 30, 2026, we completed the 2026 Private Placement, pursuant to a Securities Purchase Agreement, dated July 28, 2026 for a $200.0 million private placement financing, under which we agreed to sell an aggregate of shares of Series A Preferred Stock (or shares of our common stock on an as-converted basis and without giving effect to any beneficial ownership limitations) at a price of $ per share (or $ per share on an as-converted basis).
|